Linked Life Data

8648384

Source:http://linkedlifedata.com/resource/pubmed/id/8648384

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8648384rdf:typepubmed:Citationlld:pubmed
pubmed-article:8648384lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:8648384lifeskim:mentionsumls-concept:C1332225lld:lifeskim
pubmed-article:8648384lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:8648384lifeskim:mentionsumls-concept:C0680730lld:lifeskim
pubmed-article:8648384lifeskim:mentionsumls-concept:C0205219lld:lifeskim
pubmed-article:8648384lifeskim:mentionsumls-concept:C0018284lld:lifeskim
pubmed-article:8648384lifeskim:mentionsumls-concept:C1317973lld:lifeskim
pubmed-article:8648384lifeskim:mentionsumls-concept:C0183683lld:lifeskim
pubmed-article:8648384lifeskim:mentionsumls-concept:C0344211lld:lifeskim
pubmed-article:8648384lifeskim:mentionsumls-concept:C1521721lld:lifeskim
pubmed-article:8648384lifeskim:mentionsumls-concept:C0072146lld:lifeskim
pubmed-article:8648384lifeskim:mentionsumls-concept:C0920321lld:lifeskim
pubmed-article:8648384lifeskim:mentionsumls-concept:C1148554lld:lifeskim
pubmed-article:8648384lifeskim:mentionsumls-concept:C1171411lld:lifeskim
pubmed-article:8648384pubmed:issue4lld:pubmed
pubmed-article:8648384pubmed:dateCreated1996-7-25lld:pubmed
pubmed-article:8648384pubmed:abstractTextThe aim of this study was to determine the maximum-tolerated dose (MTD) of cyclophosphamide, doxorubicin, etoposide, prednisone, bleomycin, cytarabine, methotrexate, and leucovorin (ProMACE-CytaBOM) when the myelotoxic drugs cyclophosphamide, doxorubicin, etoposide, and cytarabine are escalated.lld:pubmed
pubmed-article:8648384pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648384pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648384pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648384pubmed:languageenglld:pubmed
pubmed-article:8648384pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648384pubmed:citationSubsetIMlld:pubmed
pubmed-article:8648384pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648384pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648384pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648384pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648384pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648384pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648384pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648384pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648384pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648384pubmed:statusMEDLINElld:pubmed
pubmed-article:8648384pubmed:monthAprlld:pubmed
pubmed-article:8648384pubmed:issn0732-183Xlld:pubmed
pubmed-article:8648384pubmed:authorpubmed-author:AndersonJJlld:pubmed
pubmed-article:8648384pubmed:authorpubmed-author:GordonL ILIlld:pubmed
pubmed-article:8648384pubmed:authorpubmed-author:GlickJJlld:pubmed
pubmed-article:8648384pubmed:authorpubmed-author:WiltonDDlld:pubmed
pubmed-article:8648384pubmed:authorpubmed-author:HabermannT...lld:pubmed
pubmed-article:8648384pubmed:authorpubmed-author:SchilderR JRJlld:pubmed
pubmed-article:8648384pubmed:authorpubmed-author:CassilethPPlld:pubmed
pubmed-article:8648384pubmed:issnTypePrintlld:pubmed
pubmed-article:8648384pubmed:volume14lld:pubmed
pubmed-article:8648384pubmed:ownerNLMlld:pubmed
pubmed-article:8648384pubmed:authorsCompleteYlld:pubmed
pubmed-article:8648384pubmed:pagination1275-81lld:pubmed
pubmed-article:8648384pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:meshHeadingpubmed-meshheading:8648384-...lld:pubmed
pubmed-article:8648384pubmed:year1996lld:pubmed
pubmed-article:8648384pubmed:articleTitlePhase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.lld:pubmed
pubmed-article:8648384pubmed:affiliationDivision of Hematology/Oncology, Department of Medicine, Northwestern University Medical School, Chicago, IL, USA.lld:pubmed
pubmed-article:8648384pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8648384pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:8648384pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:8648384pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8648384lld:pubmed